Evidence map›Paper›PMID 37047718›Full record

ArticleInternational journal of molecular sciences2023

A Dual-Function "TRE-Lox" System for Genetic Deletion or Reversible, Titratable, and Near-Complete Downregulation of Cathepsin D.

Heather M Terron, Derek S Maranan, Luke A Burgard, Frank M LaFerla, Shelley Lane, Malcolm A Leissring

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Heather M TerronInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA 92697, USA.
Derek S MarananInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA 92697, USA.
Luke A BurgardInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA 92697, USA.
Frank M LaFerlaInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA 92697, USA.
Shelley LaneInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA 92697, USA.
Malcolm A LeissringInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA 92697, USA.ORCID 0000-0001-7185-4255
University of California, Irvine · US

Funding

Temporal and Spatial Aspects of Amyloidogenesis in Sporadic Alzheimer DiseaseR01AG066928 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI FRANK M LAFERLA · 2021 to 2026
$3.6M
NIA NIH HHS R01 AG066928NIH HHS R01 AG066928
6 · The paper itself

Abstract

Commonly employed methods for reversibly disrupting gene expression, such as those based on RNAi or CRISPRi, are rarely capable of achieving >80-90% downregulation, making them unsuitable for targeting genes that require more complete disruption to elicit a phenotype. Genetic deletion, on the other hand, while enabling complete disruption of target genes, often produces undesirable irreversible consequences such as cytotoxicity or cell death. Here we describe the design, development, and detailed characterization of a dual-function "TRE-Lox" system for effecting either (a) doxycycline (Dox)-mediated downregulation or (b) genetic deletion of a target gene-the lysosomal aspartyl protease cathepsin D (CatD)-based on targeted insertion of a tetracycline-response element (TRE) and two LoxP sites into the 5' end of the endogenous CatD gene (

Indexed as

Cathepsin DFibroblastsAnimalsDown-RegulationDoxycyclineMiceResponse ElementsTetracyclineCathepsin DDoxycyclineTetracyclineAlzheimer diseasecathepsin DCre-Lox technologyCRISPRgene regulationtetracycline regulatory element

Identifiers

PMID37047718
PMCPMC10095275
OpenAlexW4362635543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.